RecruitingPhase 4NCT02357654

GnRH for Luteal Support in IVF/ICSI/FET Cycles


Sponsor

University Reproductive Associates

Enrollment

350 participants

Start Date

Nov 1, 2015

Study Type

INTERVENTIONAL

Conditions

Summary

During IVF cycles an embryo is generally placed into the uterine cavity between 3 and 5 days after fertilization. For a successful pregnancy to take place, that embryo must then implant in the properly primed and staged endometrium, which subsequently must continue to develop to accommodate the growing and maturing embryo and then fetus. This process is normally regulated by hormonal interactions between the fetal, endometrial and luteal tissue. It has been found that after IVF additional support for the endometrium with progesterone improves implantation and subsequent live birth rates in IVF cycle . Recent data has shown that additional supplementation with a single administration of a GnRH agonist around the time the time of embryo transfer may further enhance these rates .


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 40 Years

Inclusion Criteria1

  • women undergoing IVF/ICSI or frozen embryo transfers (FET) that less than 40 years old.

Exclusion Criteria1

  • day 3 transfers

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGnRH

single shot of GnRH agonist

DRUGplacebo

placebo


Locations(1)

University Reproductive Associates

Hasbrouck Heights, New Jersey, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02357654


Related Trials